Blurbs

Lantheus (LNTH) Receives a Buy from Leerink Partners

In a report issued on January 24, Danielle Antalffy from Leerink Partners maintained a Buy rating on Lantheus (LNTHResearch Report), with a price target of $34.00. The company’s shares closed last Thursday at $27.75.

According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lantheus with a $34.00 average price target.

See the top stocks recommended by analysts >>

Lantheus’ market cap is currently $1.88B and has a P/E ratio of -54.27.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.

Read More on LNTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed